Last 12 months
Inside the activity.
0 purchase rows · 31 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 5 |
| Dec 2025 | 0 | 4 |
| Jan 2026 | 0 | 4 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 3 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 2 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 1 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2020 Filed Mar 5, 2020 19:33 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 4,739 | $166.65 | $789,757.19 |
DisclosureSEC source: 0001127602-20-009574 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,564 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $163.15 to 171.16. The price reported above reflects the weighted average sale price. Read SEC document |
| March 03, 2020 Filed Mar 5, 2020 19:33 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 4,739 | $58.24 | $275,999.36 |
DisclosureSEC source: 0001127602-20-009574 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 22:19 UTC |
Burt CarolDirector
|
SaleResMed Common Stock | 10,000 | $164.90 | $1,648,954.00 |
DisclosureSEC source: 0001127602-20-009127 · form4.xml · nonDerivative · entry 1 Burt Carol · CIK 0001493926 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Carol Burt Hilliard Trust Disclosed balance after: 13,478 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 21:15 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 1,200 | $160.50 | $192,600.00 |
DisclosureSEC source: 0001127602-20-008964 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,765 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 19:31 UTC |
Sodhi RajwantPresident, SaaS Business
|
SaleResMed Common Stock | 1,500 | $160.50 | $240,750.00 |
DisclosureSEC source: 0001127602-20-008853 · form4.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,670 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 20, 2020 Filed Feb 20, 2020 23:54 UTC |
Hollingshead JamesPresident, Sleep Business
|
Tax withholdingResMed Common Stock | 9,105 | $176.00 | $1,602,480.00 |
DisclosureSEC source: 0001127602-20-006757 · form4.xml · nonDerivative · entry 3 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,965 F1 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 2/16/2017. Read SEC document |
| February 20, 2020 Filed Feb 20, 2020 23:54 UTC |
Hollingshead JamesPresident, Sleep Business
|
GrantResMed Common Stock | 15,370 | $176.00 | $2,705,120.00 |
DisclosureSEC source: 0001127602-20-006757 · form4.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 106,070 F2 · kind: Represents performance-based restricted stock units granted on February 16, 2017. The shares were earned on February 20, 2020, when the compensation committee certified that the performance metrics were met. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 21:10 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 1,133 | $176.14 | $199,566.62 |
DisclosureSEC source: 0001127602-20-006393 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 191,774 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 18, 2020 Filed Feb 19, 2020 19:32 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,500 | $176.14 | $440,350.00 |
DisclosureSEC source: 0001127602-20-006323 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,211 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 18, 2020 Filed Feb 20, 2020 23:54 UTC |
Hollingshead JamesPresident, Sleep Business
|
Tax withholdingResMed Common Stock | 1,274 | $174.80 | $222,695.20 |
DisclosureSEC source: 0001127602-20-006757 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,700 F1 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 2/16/2017. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 21:24 UTC |
McHale RichardPresident, RC Business
|
SaleResMed Common Stock | 3,000 | $172.63 | $517,903.50 |
DisclosureSEC source: 0001127602-20-005078 · form4.xml · nonDerivative · entry 1 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,670 F1 · price: This transaction was executed in multiple trades at prices ranging from $172.59 to 172.65. The price reported above reflects the weighted average sale price. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 17:32 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 6,647 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001127602-20-005027 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 6,647 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 17:32 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 6,647 | $172.21 | $1,144,662.59 |
DisclosureSEC source: 0001127602-20-005027 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,700 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $170.82 to $172.75. The price reported above reflects the weighted average sale price. Read SEC document |
| February 10, 2020 Filed Feb 12, 2020 17:32 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 6,647 | $43.63 | $290,008.61 |
DisclosureSEC source: 0001127602-20-005027 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,347 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 18:48 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 4,739 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-20-003710 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,215 Underlying: ResMed Common Stock · 4,739 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 18:48 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 4,739 | $162.37 | $769,469.06 |
DisclosureSEC source: 0001127602-20-003710 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,564 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $159.77 to 163.93. The price reported above reflects the weighted average sale price. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 18:48 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 4,739 | $58.24 | $275,999.36 |
DisclosureSEC source: 0001127602-20-003710 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 18:25 UTC |
Sodhi RajwantPresident, SaaS Business
|
SaleResMed Common Stock | 1,350 | $159.46 | $215,271.00 |
DisclosureSEC source: 0001127602-20-003706 · form4.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,170 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| February 03, 2020 Filed Feb 5, 2020 18:22 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 1,200 | $159.46 | $191,352.00 |
DisclosureSEC source: 0001127602-20-003705 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 91,974 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 15, 2020 Filed Jan 18, 2020 00:37 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,500 | $158.43 | $396,075.00 |
DisclosureSEC source: 0001127602-20-001962 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,711 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 15, 2020 Filed Jan 17, 2020 22:44 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 1,264 | $158.43 | $200,255.52 |
DisclosureSEC source: 0001127602-20-001950 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 150,780 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 00:34 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 6,651 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001127602-20-001582 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,647 Underlying: ResMed Common Stock · 6,651 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 00:34 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 6,651 | $157.43 | $1,047,054.29 |
DisclosureSEC source: 0001127602-20-001582 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,700 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $156.44 to $158.49. The price reported above reflects the weighted average sale price. Read SEC document |
| January 13, 2020 Filed Jan 15, 2020 00:34 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 6,651 | $43.63 | $290,183.13 |
DisclosureSEC source: 0001127602-20-001582 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 03, 2020 Filed Jan 6, 2020 21:16 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 4,739 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-20-001127 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,954 Underlying: ResMed Common Stock · 4,739 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| January 03, 2020 Filed Jan 6, 2020 21:16 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 4,739 | $155.25 | $735,729.75 |
DisclosureSEC source: 0001127602-20-001127 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,564 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $153.53 to 155.81. The price reported above reflects the weighted average sale price. Read SEC document |
| January 03, 2020 Filed Jan 6, 2020 21:16 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 4,739 | $58.24 | $275,999.36 |
DisclosureSEC source: 0001127602-20-001127 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,303 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 17:46 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 1,200 | $155.40 | $186,480.00 |
DisclosureSEC source: 0001127602-20-001015 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,174 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 17:44 UTC |
Sodhi RajwantPresident, SaaS Business
|
SaleResMed Common Stock | 1,350 | $155.40 | $209,790.00 |
DisclosureSEC source: 0001127602-20-001013 · form4.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,520 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 20:42 UTC |
Douglas Robert AndrewPresident and COO ResMed Inc.
|
SaleResMed Common Stock | 1,302 | $154.71 | $201,432.42 |
DisclosureSEC source: 0001127602-19-035362 · form4.xml · nonDerivative · entry 1 Douglas Robert Andrew · CIK 0001352232 · President and COO ResMed Inc. 10b5-1 filing: Not disclosed Ownership: Indirect · Douglas Family Trust Disclosed balance after: 152,044 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 16, 2019 Filed Dec 18, 2019 17:41 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,500 | $154.71 | $386,775.00 |
DisclosureSEC source: 0001127602-19-035343 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,211 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 21:31 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 6,651 | $0.00 Strike: $43.63 | $0.00 |
DisclosureSEC source: 0001127602-19-034768 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,298 Underlying: ResMed Common Stock · 6,651 shares Expires 2020-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 21:31 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 6,651 | $149.64 | $995,282.24 |
DisclosureSEC source: 0001127602-19-034768 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 354,700 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $149.09 to 149.84. The price reported above reflects the weighted average sale price. Read SEC document |
| December 09, 2019 Filed Dec 11, 2019 21:31 UTC |
Farrell Michael J.Chief Executive Officer
|
Exercise / conversionResMed Common Stock | 6,651 | $43.63 | $290,183.13 |
DisclosureSEC source: 0001127602-19-034768 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 361,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 02:19 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock Options · Derivative | 4,739 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-19-034310 · form4.xml · derivative · entry 3 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,693 Underlying: ResMed Common Stock · 4,739 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F3 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 02:19 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
SaleResMed Common Stock | 4,739 | $148.94 | $705,826.66 |
DisclosureSEC source: 0001127602-19-034310 · form4.xml · nonDerivative · entry 2 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 130,564 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $147.17 to $149.94. The price reported above reflects the weighted average sale price. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 02:19 UTC |
PENDARVIS DAVIDChief Administrative Officer
|
Exercise / conversionResMed Common Stock | 4,739 | $58.24 | $275,999.36 |
DisclosureSEC source: 0001127602-19-034310 · form4.xml · nonDerivative · entry 1 PENDARVIS DAVID · CIK 0001196723 · Chief Administrative Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,943 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 02, 2019 Filed Dec 5, 2019 00:45 UTC |
Hollingshead JamesPresident, Sleep Business
|
Exercise / conversionResMed Common Stock Options · Derivative | 800 | $0.00 Strike: $58.24 | $0.00 |
DisclosureSEC source: 0001127602-19-034304 · form4.xml · derivative · entry 4 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 800 shares Expires 2022-11-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. F2 · derivative.exercise_date: Represents date options first became exercisable. Options vest 1/3 per year. Read SEC document |
| December 02, 2019 Filed Dec 5, 2019 00:45 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 800 | $149.89 | $119,912.00 |
DisclosureSEC source: 0001127602-19-034304 · form4.xml · nonDerivative · entry 3 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,374 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 02, 2019 Filed Dec 5, 2019 00:45 UTC |
Hollingshead JamesPresident, Sleep Business
|
SaleResMed Common Stock | 800 | $149.89 | $119,912.00 |
DisclosureSEC source: 0001127602-19-034304 · form4.xml · nonDerivative · entry 2 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,174 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 02, 2019 Filed Dec 5, 2019 00:45 UTC |
Hollingshead JamesPresident, Sleep Business
|
Exercise / conversionResMed Common Stock | 800 | $58.24 | $46,592.00 |
DisclosureSEC source: 0001127602-19-034304 · form4.xml · nonDerivative · entry 1 Hollingshead James · CIK 0001570610 · President, Sleep Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| December 02, 2019 Filed Dec 4, 2019 23:23 UTC |
Sodhi RajwantPresident, SaaS Business
|
SaleResMed Common Stock | 1,350 | $149.89 | $202,351.50 |
DisclosureSEC source: 0001127602-19-034281 · form4.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,870 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 27, 2019 Filed Dec 2, 2019 21:35 UTC |
Gill HarjitDirector
|
Tax withholdingResMed Common Stock | 102 | $143.88 | $14,675.76 |
DisclosureSEC source: 0001127602-19-033988 · form4.xml · nonDerivative · entry 1 Gill Harjit · CIK 0001759311 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,158 Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 01:36 UTC |
Farrell Michael J.Chief Executive Officer
|
SaleResMed Common Stock | 1,370 | $149.26 | $204,488.94 |
DisclosureSEC source: 0001127602-19-033784 · form4.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Lisette & Michael Farrell Family Foundation Disclosed balance after: 0 Read SEC document |
| November 26, 2019 Filed Nov 28, 2019 00:55 UTC |
Sandercock BrettChief Financial Officer
|
SaleResMed Common Stock | 2,500 | $147.00 | $367,500.00 |
DisclosureSEC source: 0001127602-19-033849 · form4.xml · nonDerivative · entry 1 Sandercock Brett · CIK 0001346064 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,711 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan. Read SEC document |
| November 25, 2019 Filed Nov 26, 2019 23:28 UTC |
McHale RichardPresident, RC Business
|
SaleResMed Common Stock | 3,000 | $146.10 | $438,285.00 |
DisclosureSEC source: 0001127602-19-033779 · form4.xml · nonDerivative · entry 1 McHale Richard · CIK 0001715326 · President, RC Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,670 F1 · price: This transaction was executed in multiple trades at prices ranging from $146.07 to $146.19. The price reported above reflects the weighted average sale price. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 01:36 UTC |
Farrell Michael J.Chief Executive Officer
|
GiftResMed Common Stock | 1,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-033784 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Lisette & Michael Farrell Family Foundation Disclosed balance after: 1,370 F1 · kind: Represents a gift to the Lisette and Michael Farrell Family Foundation, a 501(c)(3) non-profit corporation. F2 · ownership.nature: Mr. and Mrs. Farrell retain dispositive power over foundation holdings. Read SEC document |
| November 25, 2019 Filed Nov 27, 2019 01:36 UTC |
Farrell Michael J.Chief Executive Officer
|
GiftResMed Common Stock | 1,370 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-033784 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Lisette and Michael Farrell Family Trust Disclosed balance after: 8,970 F1 · kind: Represents a gift to the Lisette and Michael Farrell Family Foundation, a 501(c)(3) non-profit corporation. Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 20:46 UTC |
Sodhi RajwantPresident, SaaS Business
|
Tax withholdingResMed Common Stock | 13,161 | $146.34 | $1,925,980.74 |
DisclosureSEC source: 0001127602-19-033552 · form4.xml · nonDerivative · entry 2 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,220 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based Restricted Stock Units granted on 11/16/2016. Read SEC document |
| November 21, 2019 Filed Nov 22, 2019 20:46 UTC |
Sodhi RajwantPresident, SaaS Business
|
GrantResMed Common Stock | 23,594 | $146.34 | $3,452,745.96 |
DisclosureSEC source: 0001127602-19-033552 · form4.xml · nonDerivative · entry 1 Sodhi Rajwant · CIK 0001715325 · President, SaaS Business 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,381 F1 · kind: Represents performance-based restricted stock units granted on November 16, 2016. The shares were earned on November 21, 2019, when the compensation committee certified that the performance metrics were met. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.